MK-6552 + Placebo
Phase 1Terminated 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Narcolepsy
Conditions
Narcolepsy
Trial Timeline
Jan 24, 2024 → Oct 23, 2024
NCT ID
NCT06179407About MK-6552 + Placebo
MK-6552 + Placebo is a phase 1 stage product being developed by Merck for Narcolepsy. The current trial status is terminated. This product is registered under clinical trial identifier NCT06179407. Target conditions include Narcolepsy.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06179407 | Phase 1 | Terminated |
Competing Products
20 competing products in Narcolepsy
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| E2086 + E2086 Placebo + Active Comparator + Active Comparator Placebo | Eisai | Phase 1 | 33 |
| Sodium Oxybate (Xyrem) | UCB | Phase 1 | 30 |
| JZP-110 + Placebo | Jazz Pharmaceuticals | Phase 2 | 49 |
| ADX-N05 + Placebo | Jazz Pharmaceuticals | Phase 2 | 49 |
| Xyrem | Jazz Pharmaceuticals | Phase 3 | 74 |
| JZP258 | Jazz Pharmaceuticals | Approved | 82 |
| ADX-N05 + Placebo | Jazz Pharmaceuticals | Phase 2 | 49 |
| Xyrem (sodium oxybate) oral solution | Jazz Pharmaceuticals | Phase 3 | 74 |
| JZP-258 | Jazz Pharmaceuticals | Approved | 82 |
| JZP441 + Matching Placebo | Jazz Pharmaceuticals | Phase 1 | 30 |
| Xyrem + Xyrem Placebo + Modafinil at established dose + Modafinil (Placebo) | Jazz Pharmaceuticals | Phase 3 | 74 |
| JZP-110 + Placebo oral tablet | Jazz Pharmaceuticals | Phase 3 | 74 |
| JZP-258 | Jazz Pharmaceuticals | Phase 3 | 74 |
| Transition from Xyrem to Xywav | Jazz Pharmaceuticals | Pre-clinical | 20 |
| JZP-110 | Jazz Pharmaceuticals | Phase 3 | 74 |
| Sunosi (solriamfetol) + Other prescription wake-promoting medications or stimulants | Axsome Therapeutics | Pre-clinical | 20 |
| AXS-12 (reboxetine) + Placebo | Axsome Therapeutics | Phase 3 | 74 |
| Solriamfetol 150 mg Oral Tablet | Axsome Therapeutics | Phase 1 | 30 |
| AXS-12 (Reboxetine) + Placebo | Axsome Therapeutics | Phase 2 | 49 |
| AXS-12 (reboxetine) + Placebo | Axsome Therapeutics | Phase 3 | 74 |